Basilea Pharmaceutica (BPMUF)
(Delayed Data from OTC)
$47.00 USD
0.00 (0.00%)
Updated Jul 17, 2024 02:00 PM ET
3-Hold of 5 3
B Value D Growth D Momentum D VGM
Cash flow Statements
Fiscal Year End for Basilea Pharmaceutica AG falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | 11.64 | 12.73 | -7.47 | -15.70 | -22.57 |
Depreciation/Amortization & Depletion | 1.76 | 1.15 | 0.82 | 1.27 | 1.65 |
Net Change from Assets/Liabilities | -5.82 | -11.93 | -36.44 | -37.76 | -42.52 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 8.29 | 5.44 | 8.06 | -5.55 | -0.81 |
Net Cash From Operating Activities | 15.87 | 7.39 | -35.03 | -57.74 | -64.25 |
Property & Equipment | -0.91 | -3.29 | -0.62 | 17.60 | -0.30 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | -1.75 | 0.00 | 0.00 |
Investments | 0.00 | 99.50 | 6.59 | -54.42 | 0.00 |
Other Investing Activities | -0.25 | -0.17 | -0.31 | -0.47 | -0.11 |
Net Cash from Investing Activities | -1.15 | 96.04 | 3.91 | -37.29 | -0.41 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 2.24 | 4.64 | 43.60 | 5.13 | 1.32 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | -66.07 | 0.00 | 0.00 | 103.55 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | -52.05 | -25.40 | -60.61 | 0.00 |
Net Cash from Financing Activities | -63.83 | -47.41 | 18.21 | 48.07 | 1.32 |
Effect of Exchange Rate Changes | -0.17 | 0.16 | 0.55 | -0.81 | 0.07 |
Net Change In Cash & Equivalents | -49.28 | 56.18 | -12.37 | -47.77 | -63.27 |
Cash at Beginning of Period | 120.93 | 57.59 | 72.49 | 118.44 | 175.04 |
Cash at End of Period | 71.65 | 113.77 | 60.12 | 70.67 | 111.77 |
Diluted Net EPS | 0.96 | 1.07 | -0.64 | -1.53 | -2.09 |
Fiscal Year End for Basilea Pharmaceutica AG falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | NA | 11.64 | NA | 35.42 |
Depreciation/Amortization & Depletion | NA | NA | 1.76 | NA | 0.84 |
Net Change from Assets/Liabilities | NA | NA | -5.82 | NA | -14.53 |
Net Cash from Discontinued Operations | NA | NA | 0.00 | NA | NA |
Other Operating Activities | NA | NA | 8.29 | NA | 2.59 |
Net Cash From Operating Activities | NA | NA | 15.87 | NA | 24.32 |
Property & Equipment | NA | NA | -0.91 | NA | -0.35 |
Acquisition/ Disposition of Subsidiaries | NA | NA | 0.00 | NA | NA |
Investments | NA | NA | 0.00 | NA | NA |
Other Investing Activities | NA | NA | -0.25 | NA | -0.08 |
Net Cash from Investing Activities | NA | NA | -1.15 | NA | -0.43 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | NA | 2.24 | NA | 1.50 |
Issuance (Repayment) of Debt | NA | NA | 0.00 | NA | NA |
Increase (Decrease) Short-Term Debt | NA | NA | -66.07 | NA | -20.50 |
Payment of Dividends & Other Distributions | NA | NA | 0.00 | NA | NA |
Other Financing Activities | NA | NA | 0.00 | NA | NA |
Net Cash from Financing Activities | NA | NA | -63.83 | NA | -19.00 |
Effect of Exchange Rate Changes | NA | NA | -0.17 | NA | -0.01 |
Net Change In Cash & Equivalents | NA | NA | -49.29 | NA | 4.87 |
Cash at Beginning of Period | NA | NA | 120.93 | NA | 120.77 |
Cash at End of Period | NA | NA | 71.65 | NA | 125.64 |
Diluted Net EPS | NA | NA | NA | NA | NA |